



Deloitte.

CGT Vantage™

A powerful platform
for innovation

Converge™
by Deloitte

A software-as-a-service solution designed to orchestrate the end-to-end patient treatment journey for cell and gene therapies.

WHAT IS IT?

Cell and gene therapies (CGTs) have emerged as one of the fastestgrowing sectors within the life sciences industry. The CGT supply chain is more complex than traditional pharma, requiring more stakeholders and touchpoints. Organizations can simplify and orchestrate this end-to-end journey using CGT Vantage.

WHO AND WHAT DOES IT ENABLE?

- **CGT manufacturers** to configure workflows for clinical trials and commercial therapies, manage manufacturing schedules, and provide real-time updates to therapy orders.
- **Health care providers** to refer, enroll, schedule, and order therapies for their patients across manufacturers and therapies; monitor and orchestrate patient journeys with chain of identity COI and chain of custody COC tracking through drug product infusion.
- **Ecosystem partners** to engage and seamlessly integrate to provide insights on the value-added services offered by them as part of the patient treatment journey.



REALIZE THE POTENTIAL BENEFITS OF CGT VANTAGE:

Provider


Provides access to a single, standardized portal to schedule patient treatments regardless of therapy or manufacturer.

Manufacturer

Allows manufacturers to launch multiple therapies quickly, ensure operational transparency, and reduce time to market while providing complete tracking of COI and COC across the patient treatment journey.

Ecosystem Partners

Provides standardized APIs for integrations into external systems to streamline the data exchange and provide operational transparency across the patient treatment journey.



SURVEY RESPONSES WERE DIVERSIFIED ACROSS:



Secure, scalable, cloud-based

Hosted on AWS Cloud, this Software-as-a-Service solution is fully managed and operated by Deloitte, with multi-tenant capabilities that are GxP- and HIPAA-compliant.



Standardized integrations

Data exchanges to and from manufacturers and other ecosystem partners are handled using industry-leading API patterns.



Flexible model

As a modularized product, the platform enables manufacturers to subscribe to specific modules that best support their business processes.



Standardized, configurable portal

From subject referral, to enrollment and order management, the standardized user interface for providers serves as a foundation for all CGT business process workflows while being configurable by the manufacturer at a therapy level.



COI and COC management

A standardized process for generation of COI, barcoding, and labels, including tracking of COC with all stake holders and easy COC report generation.



Flexible journey milestones

Provide flexible workflows for different types of variations in the patient journey. Manufacturers can then set up milestones as individual touchpoints on the patient treatment journey.



Start the conversation

Visit www2.deloitte.com/us/CGTVantage for more information

Siddharth Karia

Principal, Deloitte Consulting LLP
convergehealth@deloitte.com

Rajesh Singh

Managing Director, Deloitte Consulting LLP
convergehealth@deloitte.com

Hussain Mooraj

Principal, Deloitte Consulting LLP
convergehealth@deloitte.com

Deloitte.

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity. Please see www.deloitte.com/about for a detailed description of the legal structure of Deloitte Touche Tohmatsu Limited and its member firms. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries. Certain services may not be available to attest clients under the rules and regulations of public accounting.

This publication contains general information only and Deloitte is not, by means of this publication, rendering accounting, business, financial, investment, legal, tax, or other professional advice or services. This publication is not a substitute for such professional advice or services, nor should it be used as a basis for any decision or action that may affect your business. Before making any decision or taking any action that may affect your business, you should consult a qualified professional advisor. Deloitte shall not be responsible for any loss sustained by any person who relies on this publication.

Copyright © 2025 Deloitte Development LLC. All rights reserved.